This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AbbVie (ABBV) Signs New Cancer/Immunology Deal With Frontier
by Zacks Equity Research
AbbVie (ABBV) signs a global deal with Frontier Medicines to make innovative therapies and E3 degraders against difficult-to-drug targets.
Roche's (RHHBY) Xolair Gets FDA Nod for Label Expansion
by Zacks Equity Research
Roche (RHHBY) wins FDA approval of the label expansion of Xolair along with EUA for a serology test.
Blueprint Medicines' (BPMC) Gavreto Approved for Thyroid Cancer
by Zacks Equity Research
The FDA grants accelerated nod to Blueprint Medicines' (BPMC) Gavreto for treating patients with advanced/metastatic RET-altered thyroid cancer.
Pharma Stock Roundup: AZN COVID-19 Vaccine Interim Data, PFE Emergency Use Appeal
by Kinjel Shah
AstraZeneca (AZN) COVID-19 vaccine candidate proves effective in late-stage study. Pfizer (PFE) seeks Emergency use for its COVID-19 vaccine candidate.
Bristol Myers' (BMY) Opdivo Wins EC Nod for Esophageal Cancer
by Zacks Equity Research
Bristol Myers (BMY) obtains EC approval for Opdivo as a second-line treatment for unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma.
Roche (RHHBY) Gets FDA Nod for Influenza Drug Label Expansion
by Zacks Equity Research
Roche (RHHBY) gets FDA approval for Xofluza to prevent influenza in people 12 years of age and older following contact with someone with influenza.
Roche's (RHHBY) Influenza Drug Gets Positive CHMP Opinion
by Zacks Equity Research
Roche's (RHHBY) influenza drug Xofluza and Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) get a positive CHMP opinion.
Pharma Stock Roundup: PFE Coronavirus Data, FDA Emergency Tag for LLY COVID-19 Drug
by Kinjel Shah
Eli Lilly (LLY) and Pfizer (PFE) provide updates on their coronavirus vaccine/antibody candidates.
Puma (PBYI) Down 8% on Q3 Earnings Lag, Nerlynx Sales View Cut
by Zacks Equity Research
Puma Biotech (PBYI) falls more than 8% as it misses on both earnings and revenues in the third quarter of 2020. The company trims its 2020 revenue guidance for Nerlynx.
ImmunoGen (IMGN) Q3 Earnings & Sales Top, Pipeline on Track
by Zacks Equity Research
ImmunoGen (IMGN) reports encouraging third-quarter results. Top-line data readout from pivotal studies on its lead candidate, mirvetuximab soravtansine, remains on track.
Biogen Alzheimer's Drug Aducanumab Gets Rejected by FDA Panel
by Zacks Equity Research
If Biogen's (BIIB) aducanumab is approved by the FDA going forward, it will become the first medicine to be approved to reduce the clinical decline associated with Alzheimer's disease.
TEVA Posts In-Line Q3 Earnings, Lowers Sales View, Stock Down
by Zacks Equity Research
TEVA's earnings match estimates while sales miss the same for third-quarter 2020. It lowers its previously issued sales guidance for 2020. Stock down.
Exelixis' (EXEL) Q3 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Exelixis (EXEL) posts a wider-than-expected loss for the third quarter but beats on revenues.
Prothena (PRTA) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Prothena (PRTA) misses earnings and sales estimates in the third quarter of 2020.
Halozyme (HALO) Q3 Earnings Top, 2020 View Up, Stock Rises
by Zacks Equity Research
Halozyme (HALO) reports better-than-expected third-quarter results. The company raises outlook for the year anticipating higher royalties.
Seagens (SGEN) Q3 Earnings Rise Y/Y, Adcetris Sales View Cut
by Zacks Equity Research
Seagen's (SGEN) bottom line grows year over year in Q3 while revenues beat estimates. The company lowers the sales guidance for its lead product Adcetris.
AbbVie (ABBV) Beats on Q3 Earnings & Sales, Ups 2020 Guidance
by Zacks Equity Research
AbbVie (ABBV) beats on third-quarter 2020 earnings and revenues. Shares up in pre-market trading.
Amgen (AMGN) Q3 Earnings Top, Prolia, Biosimilars Drive Sales
by Zacks Equity Research
Amgen (AMGN) beats Q3 estimates for both earnings and sales. It slightly narrows its previously issued sales guidance for 2020 while raising its earnings range.
Blueprint Medicines (BPMC) Q3 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
Blueprint Medicines' (BPMC) both bottom and the top line trump estimates in Q3. Ayvakit's sales rise sequentially.
Top Research Reports for UnitedHealth, Adobe & Pfizer
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group (UNH), Adobe (ADBE) and Pfizer (PFE).
Will Humira, Cancer Drugs Drive AbbVie (ABBV) Q3 Earnings?
by Zacks Equity Research
AbbVie's (ABBV) Q3 top-line results are expected to reflect the impact of coronavirus on sales of Humira, Imbruvica and Venclexta.
Novartis' (NVS) Q3 Earnings Surpass Estimates, Sales Miss
by Zacks Equity Research
Novartis' (NVS) third-quarter 2020 sales take a hit due to the coronavirus pandemic but earnings beat estimates.
Roche (RHHBY) Inks Deal to Develop Oral Coronavirus Treatment
by Zacks Equity Research
Roche (RHHBY) signs a contract with privately-held Atea Pharmaceuticals for jointly developing AT-527, an oral treatment for COVID-19 patients.
Amgen (AMGN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on whether Amgen's (AMGN) sales have recovered in the third quarter from the COVID-19 effect.
Prothena (PRTA) to Advance Parkinson's Disease Drug to Phase II
by Zacks Equity Research
Prothena (PRTA) and partner Roche (RHHBY) plan to advance prasinezumab into a phase IIb study in patients with early Parkinson's disease.